Two simultaneous developments in the NEC preterm infant formula litigation are forcing a reassessment of settlement value across 798 active federal cases. Missouri's appellate courts have now foreclosed one of the defense bar's most reliable tools, and the federal MDL's expert-exclusion record has been broken for the first time. The week of July 6, 2026 is the inflection point.
Missouri Appeals Court Upholds $495 Million in Gill v. Abbott and Rejects the Learned-Intermediary Defense
The Missouri Court of Appeals' May 2026 affirmance of the Gill v. Abbott Laboratories verdict preserved $95 million in compensatory damages and $400 million in punitive damages. The appellate holding extended well beyond the dollar figure. The court rejected the learned-intermediary doctrine on the ground that preterm cow-milk-based infant formula is food, not a prescription drug, and that the intermediary-warning rationale therefore does not apply.
That reasoning has national reach. Defendants in NEC and formula-product-liability cases have consistently argued that adequate warnings to neonatologists satisfy the duty to warn end-users, shielding manufacturers from liability to parents and infants. Under Missouri's appellate authority, that argument is closed when the product is food-classified. Plaintiff counsel in other jurisdictions will use Gill as persuasive authority even in federal courts applying different state law, particularly in early-stage motions where the doctrine's applicability is being tested for the first time. TorHoerman Law served as lead counsel for the plaintiff.
Takeaway: The learned-intermediary doctrine is unavailable as a defense where infant formula is classified as food under Missouri appellate authority, and plaintiff counsel in any pending NEC case facing a learned-intermediary motion should cite Gill v. Abbott Laboratories in the response brief.
Inman v. Mead Johnson Opens July 6 as MDL 3026's First Daubert Survivor
Jury selection in Inman v. Mead Johnson (MDL 3026, S.D. Ill., Judge Pallmeyer) begins July 6, 2026. The trial carries particular significance because plaintiff epidemiologist Dr. Logan Spector's testimony survived Daubert challenge and will reach the jury. That has not happened before in this MDL.
Abbott's record in the federal MDL going into this trial was a clean sweep: three prior bellwether cases ended at summary judgment in 2025 after Daubert exclusions blocked plaintiff causation experts. Defense counsel used that record to argue that no plaintiff expert could get to a jury on causation in federal court. Dr. Spector's survival ends that argument. Even if Inman produces a defense verdict on the merits, the expert-exclusion narrative has been retired, and individual case valuations across all 798 pending federal plaintiffs will need to be recalculated accordingly. A plaintiff verdict in Inman will accelerate global settlement pressure on Abbott and Mead Johnson substantially.
Takeaway: Dr. Spector's Daubert survival in Inman v. Mead Johnson is the first crack in defendants' expert-exclusion record across MDL 3026's history, and any plaintiff with a pending NEC case in the federal system now holds a stronger hand at the negotiating table than at any prior point in the litigation.
Four Additional 2026 Verdicts from $35 Million to $108.6 Million
The NEC litigation dominates current headlines, but four other 2026 malpractice verdicts demonstrate plaintiff momentum across unrelated theories and jurisdictions.
Philadelphia County Common Pleas Court returned a $108.6 million verdict in March 2026 in a birth-injury case. Plaintiff alleged that a 2018 delivery resulted in permanent brain injury from improper forceps use and related obstetric care failures. The Philadelphia County jury pool has a documented history of large awards in birth-trauma cases, and this verdict is consistent with that pattern.
Mobile County Circuit Court in Alabama returned a $50 million wrongful-death verdict in March 2026. The plaintiff's family alleged that providers discharged the patient despite a life-threatening coronary artery blockage. The liability theory rested on failure-to-diagnose and failure-to-treat, both squarely within the standard-of-care framework that governs emergency-department and hospitalist practice.
Cook County Circuit Court in Illinois produced a $56 million verdict, with post-judgment interest pushing the recoverable total past $66 million, in a case where a physician failed to arrange postoperative monitoring and the patient died from untreated internal hemorrhage while unattended in the recovery room. Plaintiff counsel characterized the award as among the largest med-mal verdicts in Illinois history. The failure-to-monitor theory here is a systems failure, not a surgical error, which matters for any firm with cases involving post-procedure gaps in facility oversight protocols.
In a separate Philadelphia County matter, plaintiff Isis Spencer obtained a $35 million verdict after a surgeon performed a full hysterectomy based on contaminated biopsy slides at Main Line Health that generated a false-positive cancer diagnosis. A subsequent Penn Medicine biopsy revealed no malignancy. The cross-institutional pathology-error theory is increasingly viable as hospital systems route specimens across multiple lab facilities.
Takeaway: The Spencer verdict in Philadelphia County establishes that cross-institutional pathology error, where a false-positive diagnosis at one facility leads to irreversible surgery at another, is a viable and substantial-verdict theory in 2026.
GAO-26-107619: A Government Accountability Document for Device-Defect Litigation
A February 2026 GAO report formally criticized HHS and FDA for failing to effectively oversee the medical device recall process and for maintaining an ongoing manufacturing-plant inspection backlog. This is not a plaintiff expert's report or an internal company document disclosed in discovery. It is a nonpartisan Government Accountability Office report issued to Congress, stating that the agency responsible for device-safety oversight was not performing that function.
In device-defect litigation, the source of a negligence narrative matters. An FDA inspection backlog documented in a GAO report is usable in a way that a company internal audit or a hired expert's opinion is not. Plaintiff counsel in active device-defect cases involving implants, surgical instruments, or monitoring equipment should review GAO-26-107619 for applicability to the specific production timeline of the device at issue. Where a device was manufactured during a period covered by the documented inspection backlog, that report supports a systemic-oversight-failure theory at the pleading stage and in opposition to summary judgment.
Takeaway: GAO-26-107619's documented FDA inspection backlog is a government-sourced negligence narrative available to plaintiff counsel in device-defect cases where the challenged device was manufactured during the period the report covers.
Telehealth Standard-of-Care Parity and What It Means for Lien-Track Providers
State licensing boards in Florida and elsewhere now apply the same standard of care to telehealth encounters as to in-person visits. That parity rule has been settled in most jurisdictions. The operational risk it creates for providers treating personal injury plaintiffs on a medical lien basis is less widely recognized.
Standard malpractice policies may not cover remote encounters without a specific telehealth endorsement. Gallagher Healthcare has flagged this coverage gap to the industry. A surgery center, imaging clinic, or specialist practice that sees a PI patient via telemedicine for a post-procedure follow-up, documents that encounter in the lien file, and later faces a malpractice claim may find that its carrier excludes the remote encounter from coverage. Standard-of-care parity means liability exposure is equivalent to an in-person visit; the policy may not match that exposure without an explicit endorsement.
Providers listed in lien-tracking directories should confirm before the next renewal cycle whether their malpractice policy includes a telehealth endorsement that covers the specific types of remote encounters they conduct with PI patients. This is not a hypothetical exposure. As telehealth volume in post-acute and specialist PI care has grown, the gap between actual practice and policy language has widened.
For plaintiff counsel, the parity rule has a parallel implication: a telemedicine provider who fails to order appropriate imaging or refer a PI patient for in-person evaluation faces the same standard-of-care analysis as an in-office provider under identical clinical facts.
Takeaway: Providers treating PI plaintiffs on lien via telemedicine should obtain an explicit telehealth endorsement from their malpractice carrier before the next renewal, because standard-of-care parity makes remote encounters equally susceptible to liability claims as in-person visits.
The structural question heading into the July 6 bellwether: whether a single adverse verdict in Inman will be sufficient to bring Abbott and Mead Johnson to a global settlement table, or whether defendants with 797 remaining cases can absorb one trial loss and continue the case-by-case Daubert strategy that worked in 2025. The answer is not yet known, and it will define the settlement value of every NEC case in MDL 3026 for the remainder of 2026.